Clinical research

SUMMIT: Tirzepatide in heart failure with preserved ejection fraction and obesity

Phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre. 731 randomised 1:1, over 52 weeks to the symptom endpoint, with event follow-up. Sponsor: Eli Lilly and Company.

SUMMIT (NCT04847557) tested tirzepatide once weekly at maximum tolerated dose at 5 mg, 10 mg or 15 mg against placebo in adults with heart failure with preserved ejection fraction and obesity (bmi 30 or above), with or without type 2 diabetes.A 38% reduction in the combined endpoint of cardiovascular death and worsening heart-failure events, with improvement in symptoms, physical limitations and exercise capacity Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

Results

A 38% reduction in the combined endpoint of cardiovascular death and worsening heart-failure events, with improvement in symptoms, physical limitations and exercise capacity

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

Industry-funded. Restricted to obesity-related HFpEF, a specific phenotype, so the result should not be generalised to heart failure broadly or to HFpEF without obesity. Relative risk reduction without the absolute event rate overstates the effect to most readers.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.